About

Science

Learn how we are advancing our pipeline.

About Hypertrophic Cardiomyopathy (HCM)

Moving crowd with blurs of motion.
Two people kayaking on water together.
Two people holding hands walking.

HCM is a disease of excessive heart contraction and impaired relaxation.

In hypertrophic cardiomyopathy (HCM), overactive myosin causes the myocardium to abnormally thicken. This can lead to declining cardiac performance, or how well the heart fills with and pumps blood. Symptoms can include shortness of breath, chest pain, fatigue, and fainting, which typically worsen with physical activity.

There are two kinds of HCM.

Patients can have either obstructive HCM (oHCM) or non-obstructive HCM (nHCM). In obstructive HCM, the thickened muscle impedes blood flow out of the heart causing obstruction at the left ventricular outflow tract (LVOT).

In both forms of HCM, the thickened myocardium makes it harder for the heart to contract and relax.

HCM is among the most common rare diseases.

HCM affects approximately 1 in 500 individuals in the United States. Even with the approval of targeted therapies in oHCM that have corresponded to an increase in diagnoses, HCM remains severely underdiagnosed. Many patients encounter delayed diagnosis whereas most remain frequently undiagnosed and/or misdiagnosed.

Unmet Needs

While recent advances have introduced new treatment options, many patients and clinicians continue to face challenges with complex dosing requirements and intensive monitoring protocols. Fewer than 20% of eligible oHCM patients in the US have been treated to date with targeted therapies.

Non-obstructive HCM remains an underdiagnosed condition with no approved targeted treatment options. There is a significant need for therapies that can deliver meaningful improvements with greater convenience and accessibility.

About BHB-1893

BHB-1893 is a selective, reversible small-molecule cardiac myosin inhibitor with rapid onset of action, favorable safety, and potential greater convenience. It was designed to address limitations of existing treatments through three key advantages:

Efficacy
Safety
Convenience

More than 250 clinical study participants have received BHB-1893 to date, whose experiences constitute a growing safety database.

Pipeline

Braveheart is advancing BHB-1893 through global late-stage clinical development, seeking to determine its potential as a convenient treatment requiring minimal or no dose titration.

Note: Hengrui is conducting an ongoing Phase 3 oHCM clinical trial and an ongoing Phase 2 HFpEF clinical trial of HRS-1893 in China.

Expanded Access Policy

Braveheart Bio is focused on developing precision therapies for cardiovascular disease. We believe the best way to understand the potential of our investigational candidate, BHB-1893, is to study its efficacy and safety in late-stage clinical development. While we recognize there may be potential interest in accessing BHB-1893 outside of formal clinical trials, we do not offer expanded access to BHB-1893 at this time. Currently, our efforts are focused on advancing its clinical development to obtain regulatory approvals to make it available to appropriate patients as soon as possible. Should our policy on expanded access change in the future, we will post an updated policy here. If you are a health care provider who is interested in learning more about our investigational therapy, or a physician, patient or caregiver with questions about participation in one of our clinical trials, please submit a request to info@braveheart.bio.

Braveheart Bio will acknowledge inquiries as soon as possible, usually within 5 business days of receipt. For a list of our current ongoing clinical trials, visit www.ClinicalTrials.gov.

Interested in joining our team?

Learn more about our openings.

Learn More